Therapy Areas: Respiratory
Resilience to manufacture mRNA for Moderna's COVID-19 Vaccine in Canada
9 September 2021 -

Biopharmaceutical manufacturing and technology company, National Resilience Inc, on Wednesday launched an agreement to manufacture the drug substance for the Moderna COVID-19 vaccine to ensure more people are protected around the world from the deadly COVID-19 virus.

Pursuant to the multi-year agreement, Resilience will produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario in Canada, for distribution worldwide.

Recently Moderna signed a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in the country including access to Moderna's mRNA development engine.

The MoU is expected to support Canada with direct access to rapid COVID-19 pandemic response capabilities as well as provide access to Moderna's vaccines in development for respiratory viruses.



Related Headlines